Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer
Crossref DOI link: https://doi.org/10.1007/s00520-017-3863-9
Published Online: 2017-09-18
Published Print: 2018-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Goyal, Ravi K.
Tzivelekis, Spiros
Rothman, Kenneth J.
Candrilli, Sean D.
Kaye, James A.
Funding for this research was provided by:
Amgen
License valid from 2017-09-18